Aliri Launches qPCR to Complement Existing Lineup of Multi-Omics Platforms
Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial biology solutions for drug developers, is pleased to announce the addition of quantitative polymerase chain reaction analysis (qPCR) to our extensive list of analytical services. The implementation of this technology complements our existing lineup of multi-omics platforms, making Aliri a one-stop-shop for the advanced GCP analysis of fluids and tissues.
With the launch of this service, Aliri Bioanalysis’s laboratory in Lille, France, is now equipped with the latest generation of PCR instrumentation, including the QuantStudio 7 Pro, which uses fluorescence to detect the quantity of multiple target genes in real time after each PCR cycle with high sensitivity and specificity.
Our qPCR services include:
- Scientific support for assay development and experimental design
- Sample preparation for extraction and purification from a wide range of sample types, such as liquid biopsies and FFPE material
- Pre- and post-analytical processes including nucleic acid extraction, QC, and data interpretation
- Assay validation tiered for research through to clinical testing
Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial biology solutions for drug developers, is pleased to announce the addition of quantitative polymerase chain reaction analysis (qPCR) to our extensive list of analytical services. The implementation of this technology complements our existing lineup of multi-omics platforms, making Aliri a one-stop-shop for the advanced GCP analysis of fluids and tissues.
With the launch of this service, Aliri Bioanalysis’s laboratory in Lille, France, is now equipped with the latest generation of PCR instrumentation, including the QuantStudio 7 Pro, which uses fluorescence to detect the quantity of multiple target genes in real time after each PCR cycle with high sensitivity and specificity.
Our qPCR services include:
- Scientific support for assay development and experimental design
- Sample preparation for extraction and purification from a wide range of sample types, such as liquid biopsies and FFPE material
- Pre- and post-analytical processes including nucleic acid extraction, QC, and data interpretation
- Assay validation tiered for research through to clinical testing
“The launch of this highly effective and adaptable technique creates endless opportunities to explore and analyze gene expression, and oligonucleotide-based therapies. Our scientific team has completed qPCR projects in both research and clinical trial settings and is excited to work in close collaboration with our sponsors to derisk and accelerate their programs thanks to the extension of our capabilities,” stated David Bonnel, PhDs, Global Executive Director of Aliri’s laboratory in Lille, France.
Aliri’s laboratory in Lille, France, originally ImaBiotech, has over 15 years of experience unraveling the complexities of disease using spatial biology and spatial bioanalysis. Aliri’s investment in qPCR is a representation of our team’s commitment to providing sponsors with advanced solutions to de-risk and accelerate their development programs, resulting in more effective therapies. We look forward to continuing to invest in new equipment, technology, and service offerings in 2025. For more information, visit https://aliribio.com/contact-us/.
Total Page Views: 170
